Transcript
A (0:00)
Foreign welcome to Coruscant Technologies, home of the Digital Executive Podcast. Welcome to the Digital Executive. Today's guest is Nick Aldridge. Nick aldridge has over 10 years of experience in the medical device industry. Most recently, he managed a global marketing team at Stryker focused on Revision knee, hip and limb salvage implants, and was involved in several key 3D printed product launches in the Primary and Revision knee space. Prior to joining Stryker, Nick was part of the marketing team at Ansel Healthcare, where he focused on strategic planning and mergers and acquisitions. Prior to Ansel, Nick worked in finance for two Johnson and Johnson companies, Cordis Corp. A cardiovascular endovascular company, and Ethicon Inc. A suture and surgical technologies business. Nick has a proven track record of developing strategies and driving efficient and effective marketing campaigns that deliver results well. Good afternoon Nick. Welcome to the show.
B (1:04)
Thank you. Thanks Brian. Thanks for having me.
A (1:06)
Absolutely, my friend. I really appreciate it. You're in New York this today and I am in Kansas City, so just an hour apart, but I appreciate highlighting a guest location every time and just part of my, I guess my podcast every time I start. So anyway, Nick, let's jump into your first question. As someone who moved from managing marketing at major device companies like Stryker, Johnson Johnson into a leadership role at a growing medtech innovator, how has your approach to marketing changed in an environment where the end user is a surgeon, but payers, hospitals and value metrics also matter?
B (1:40)
Yeah, Brian, this is a great question. You know, when you, when you work at some of the large strategics like Stryker or J and J, marketing tends to be pretty structured and scaled and supported by some pretty massive systems and resources, which often means you're managing global campaigns with big infrastructure. You've got the playbook, the budget and the brand equity. But when you step into a company like Orthline, you trade that infrastructure for intimacy. You're a lot closer to your customer into the outcomes that our technology is actually delivering. And when I think about, you know, the marketing side and the my career, I think the biggest change for me is thinking more holistically about influence in the space. You know, the searching is still at the center of what we do every day. But the conversation now includes ASC administrators, hospital committees, and even the payers to some extent. And each have a different definition of value, which is really what we're all chasing. So, so we've had to evolve from, you know, selling a product to really building that value narrative. So instead of just messaging features or outcomes, we're telling stories that connect across the ecosystem accuracy that builds the surgeon's confidence, efficiency that increases case volumes in an ASC, and that economics that really strengthen the ASCs or the hospital's bottom line. So, you know, that's really how we build trust and relevance in the space where, you know, technology seems to be advancing faster than adoption itself. But it's funny because, you know, I tell my team all the time that medtech marketing today isn't about the loudest message anymore. It's about the clearest value and aligning that value across every decision maker in the room.
